2022
Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes
INVESTIGATORS I, Sadeghipour P, Talasaz A, Barco S, Bakhshandeh H, Rashidi F, Rafiee F, Rezaeifar P, Jamalkhani S, Matin S, Baghizadeh E, Tahamtan O, Sharif-Kashani B, Beigmohammadi M, Farrokhpour M, Sezavar S, Payandemehr P, Dabbagh A, Moghadam K, Jimenez D, Monreal M, Maleki M, Siegerink B, Spatz E, Piazza G, Parikh S, Kirtane A, Van Tassell B, Lip G, Goldhaber S, Klok F, Krumholz H, Bikdeli B. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes. European Journal Of Internal Medicine 2022, 103: 76-83. PMID: 35879217, PMCID: PMC9212871, DOI: 10.1016/j.ejim.2022.06.014.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationPatient Health Questionnaire-2Proportion of patientsProphylactic anticoagulationIntermediate doseFunctional limitationsDepressive symptomsFunctional outcomeCOVID-19Intensive care unit hospitalizationCritically Ill PatientsMultiple organ failureSevere functional limitationsFunctional Status ScaleCoronavirus disease 2019Open labelExercise limitationAirway diseaseICU patientsOrgan failureIntensive careStatus ScaleClinical trialsGrade 3Anticoagulation2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure
Heidenreich P, Bozkurt B, Aguilar D, Allen L, Byun J, Colvin M, Deswal A, Drazner M, Dunlay S, Evers L, Fang J, Fedson S, Fonarow G, Hayek S, Hernandez A, Khazanie P, Kittleson M, Lee C, Link M, Milano C, Nnacheta L, Sandhu A, Stevenson L, Vardeny O, Vest A, Yancy C, Beckman J, O'Gara P, Al-Khatib S, Armbruster A, Birtcher K, Cigarroa J, de las Fuentes L, Deswal A, Dixon D, Fleisher L, Gentile F, Goldberger Z, Gorenek B, Haynes N, Hernandez A, Hlatky M, Joglar J, Jones W, Marine J, Mark D, Mukherjee D, Palaniappan L, Piano M, Rab T, Spatz E, Tamis-Holland J, Wijeysundera D, Woo Y. 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure. Journal Of Cardiac Failure 2022, 28: e1-e167. PMID: 35378257, DOI: 10.1016/j.cardfail.2022.02.010.Peer-Reviewed Original ResearchConceptsACCF/AHA guidelinesHeart failure guidelinesHeart failureAHA guidelinesAmerican Heart Association/American CollegeRelevant clinical trialsQuality of careComprehensive literature searchEvidence-based approachCardiology guidelinesCochrane CollaborationClinical trialsLeading causeFocused updateAmerican CollegeLiterature searchPatientsHealthcare ResearchPatient interestHuman subjectsRelevant databasesNew recommendationsCertain treatmentsGuidelinesContemporary evidence
2019
P573Effects of mobile text messaging on glycemic control in patients with coronary heart disease and diabetes mellitus: a randomized controlled trial
Huo X, Krumholz H, Bai X, Spatz E, Ding Q, Horak P, Zhao W, Gong Q, Yan X, Wu X, Li J, Li X, Spertus J, Masoudi F, Zheng X. P573Effects of mobile text messaging on glycemic control in patients with coronary heart disease and diabetes mellitus: a randomized controlled trial. European Heart Journal 2019, 40: ehz747.0184. DOI: 10.1093/eurheartj/ehz747.0184.Peer-Reviewed Original ResearchCoronary heart diseaseIntervention groupPhysical activityControl groupGlycemic controlHeart diseaseBaseline 6 monthsHigh-risk patientsText messaging programsSecondary outcome analysisMobile health interventionsText message programMean change differenceBP controlGlycemic hemoglobinHbA1c levelsLifestyle modificationUsual careDiabetes mellitusFamily Planning CommissionPrimary outcomeLifestyle recommendationsMonth followRisk factorsClinical trials
2017
A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease
Osibogun O, Ogunmoroti O, Michos ED, Spatz ES, Olubajo B, Nasir K, Maziak W. A systematic review of the associations between HIV/HCV coinfection and biomarkers of cardiovascular disease. Reviews In Medical Virology 2017, 28 PMID: 29135056, DOI: 10.1002/rmv.1953.Peer-Reviewed Original ResearchConceptsHIV/HCV coinfectionCarotid intima-media thicknessHuman immunodeficiency virusC-reactive proteinHCV coinfectionHealthy controlsCoinfected individualsCVD biomarkersEndothelial markersHepatitis C virus coinfectionBiomarkers of CVDC virus coinfectionCardiovascular disease riskIntima-media thicknessSignificant lower levelsWeb of ScienceHCV monoinfectionCVD riskVirus coinfectionImmunodeficiency virusProspective studyIL-6Clinical trialsCardiovascular diseaseCarotid plaques
2011
Statin myopathy: A common dilemma not reflected in clinical trials
Fernandez G, Spatz E, Jablecki C, Phillips P. Statin myopathy: A common dilemma not reflected in clinical trials. Cleveland Clinic Journal Of Medicine 2011, 78: 393-403. PMID: 21632911, DOI: 10.3949/ccjm.78a.10073.Peer-Reviewed Original Research